CN117883426A - Rhinitis medicine and cold medicine - Google Patents
Rhinitis medicine and cold medicine Download PDFInfo
- Publication number
- CN117883426A CN117883426A CN202410056754.2A CN202410056754A CN117883426A CN 117883426 A CN117883426 A CN 117883426A CN 202410056754 A CN202410056754 A CN 202410056754A CN 117883426 A CN117883426 A CN 117883426A
- Authority
- CN
- China
- Prior art keywords
- acetic acid
- acid solution
- medicine
- rhinitis
- cold
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 43
- 206010039083 rhinitis Diseases 0.000 title claims abstract description 40
- 229940124579 cold medicine Drugs 0.000 title abstract description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims abstract description 210
- 229940079593 drug Drugs 0.000 claims description 10
- 206010039101 Rhinorrhoea Diseases 0.000 abstract description 14
- 208000024891 symptom Diseases 0.000 abstract description 13
- 206010028748 Nasal obstruction Diseases 0.000 abstract description 9
- 210000002850 nasal mucosa Anatomy 0.000 abstract description 9
- 208000010753 nasal discharge Diseases 0.000 abstract description 7
- 241000700605 Viruses Species 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 5
- 230000000172 allergic effect Effects 0.000 abstract description 4
- 208000010668 atopic eczema Diseases 0.000 abstract description 4
- 210000003928 nasal cavity Anatomy 0.000 abstract description 4
- 230000009982 effect on human Effects 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 239000000825 pharmaceutical preparation Substances 0.000 abstract description 2
- 238000002474 experimental method Methods 0.000 description 15
- 208000036071 Rhinorrhea Diseases 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 201000009240 nasopharyngitis Diseases 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000001458 anti-acid effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000000586 desensitisation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to a rhinitis medicine and a cold medicine. The rhinitis medicine and the cold medicine comprise: 10% acetic acid solution, 14% acetic acid solution, 18% acetic acid solution, 22% acetic acid solution, 26% acetic acid solution, and 30% acetic acid solution. The rhinitis medicine and the cold medicine provided by the invention can enable nasal mucosa to be separated from allergic state within 10-20 minutes, the desensitizing speed is faster than that of the existing medicine, the desensitizing effect is that the nasal discharge can be effectively inhibited, the symptom of nasal obstruction is slowed down, meanwhile, the medicine has no obvious toxic or side effect on human body, and viruses in the nasal cavity can be inhibited.
Description
Technical Field
The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to a rhinitis medicine and a cold medicine.
Background
Rhinitis, i.e. inflammatory diseases of the nasal cavity, is an inflammation of the nasal mucosa caused by viruses, bacteria, allergens, various physicochemical factors and certain systemic diseases. Symptoms of rhinitis often include a plurality of nasal discharge, nasal obstruction and the like; among them, many nasal discharge is often sticky or mucopurulent. Rhinitis symptoms generally originate from two conditions, one of which is a single occurrence of rhinitis, such as allergic rhinitis, often manifested as runny nose; rhinitis, which is the complication of the common cold, is often accompanied by nasal obstruction and runny nose. Rhinitis has become a common disease in the whole population with changes in the global climate and spread of infection by various viruses and bacteria.
For rhinitis and cold patients, continuous flow of clear nasal discharge is an annoying symptom which can cause inconvenience and even some loss to work. The reason for the runny nose is that the nasal mucosa enters an allergic state under the induction of external factors, and the runny nose is a mechanism reaction of human body allergy to the nasal mucosa.
In general, the adverse effect of rhinitis on patients is not fatal, but is indeed a kind of pain and trouble, and can directly affect the working efficiency and the quality of life. The existing method for treating rhinitis is mostly antibiotic medicines in Western medicine and decoction treatment in traditional Chinese medicine, and is occasionally subjected to physical therapies such as surgery, acupuncture and the like.
There are several short plates in the existing treatment methods: (1) At present, when rhinitis symptoms appear in people, half of patients use antibiotic western medicines. Modern researches have confirmed that the long-term use of antibiotics has obvious side effects, so that the human body is tired by the antibiotics, the efficacy of the antibiotics is greatly reduced, the treatment difficulty of microbial infection diseases is increased, and especially the influence on the infants and the elderly patient groups is larger. (2) The existing treatment method has long effective period for desensitizing nasal mucosa, and the longer one takes days and the shorter one takes hours.
Disclosure of Invention
In order to overcome the defects in the prior art, the invention aims to provide a rhinitis medicine and a cold medicine.
The object of the invention is achieved by at least one of the following technical solutions.
The rhinitis medicine provided by the invention comprises acetic acid solution.
Further, in the rhinitis medicine, the mass percentage concentration of the acetic acid solution is more than 7%.
Further, in the rhinitis medicine, the mass percentage concentration of the acetic acid solution is 7% -30%.
Further, in the rhinitis medicine, the acetic acid solution comprises 10% acetic acid solution by mass percentage, 14% acetic acid solution by mass percentage, 18% acetic acid solution by mass percentage, 22% acetic acid solution by mass percentage, 26% acetic acid solution by mass percentage and 30% acetic acid solution by mass percentage.
The cold medicine provided by the invention comprises acetic acid solution.
Further, in the medicine for treating cold, the mass percentage concentration of the acetic acid solution is more than 7%.
Further, in the medicine for treating cold, the mass percentage concentration of the acetic acid solution is 7% -30%.
Further, in the medicine for treating cold, the acetic acid solution comprises 10% acetic acid solution by mass percentage, 14% acetic acid solution by mass percentage, 18% acetic acid solution by mass percentage, 22% acetic acid solution by mass percentage, 26% acetic acid solution by mass percentage and 30% acetic acid solution by mass percentage.
Compared with the prior art, the invention has the following advantages and beneficial effects:
the rhinitis medicine and the cold medicine provided by the invention can enable nasal mucosa to be separated from allergic state within 10-20 minutes, the desensitizing speed is faster than that of the existing medicine, the situation of flowing and nasal discharge can be effectively inhibited, the symptom of nasal obstruction is slowed down, meanwhile, the medicine has no obvious toxic or side effect on human body, and viruses in nasal cavity can be inhibited.
Detailed Description
The following examples are presented to further illustrate the practice of the invention, but are not intended to limit the practice and protection of the invention. It should be noted that the following processes, if not specifically described in detail, can be realized or understood by those skilled in the art with reference to the prior art. The reagents or apparatus used were not manufacturer-specific and were considered conventional products commercially available.
Example 1
A rhinitis medicine comprises acetic acid solution. The acetic acid solution comprises 10% of acetic acid solution, 14% of acetic acid solution, 18% of acetic acid solution, 22% of acetic acid solution, 26% of acetic acid solution and 30% of acetic acid solution.
Example 2
A medicine for treating common cold comprises acetic acid solution. The acetic acid solution comprises 10% of acetic acid solution, 14% of acetic acid solution, 18% of acetic acid solution, 22% of acetic acid solution, 26% of acetic acid solution and 30% of acetic acid solution.
Example 3
To verify the effect of the rhinitis drug of example 1 on relieving symptoms of nasal mucosa desensitization, runny nose and nasal obstruction of patients, several volunteers between 20 and 45 years old (equal in number of men and women, and weight between 45 and 70 kg) were selected, and all the volunteers had rhinitis, symptoms of runny nose and nasal obstruction, and were randomly divided into 4 groups of 10 persons each, each of which was experimental group 1, experimental group 2, control group 1 and control group 2. Wherein, the rhinitis symptoms of the volunteers of the experimental group 1 and the control group 1 are runny nose. Rhinitis symptoms of volunteers of experimental group 2 and control group 2 were nasal obstruction.
Wherein, experiment group 1 and experiment group 2 use rhinitis drugs prepared in example 1. Pure water was used for control 1 and control 2.
The method for using the rhinitis medicine in the experimental group (comprising the experimental group 1 and the experimental group 2) comprises the following steps:
Before testing, sequentially recording rhinitis symptoms of 10 volunteers, scoring the volunteers (fully dividing into 10 minutes) according to the uncomfortableness of the volunteers, sequentially opening the 10 volunteers of the experiment group 1 at a distance of 1-3 cm above the 1-3 cm, the 2-3 cm, the 4-5 cm and the 6 cm above the acetic acid solution, the acetic acid solution of 22% and the 26% acetic acid solution of 30% respectively, sealing the 6 containers (anti-acid container), sequentially arranging the 10 volunteers according to the concentration, sequentially opening the 1-2, 3-4, 5-6 bottles of the experiment group 1, sequentially placing the 1-2-3 cm above the 1-3 cm, sequentially opening the 1-3 cm above the 4-5 cm above the 6 cm, sequentially opening the acetic acid bottle at a breath rate of deep breath, selecting a number capable of inhaling the acetic acid, sequentially stopping the nasal inhalation of the volunteers at a breath rate of 1-3 cm above the bottle mouth, sequentially after the selection, finishing the experiment of the experiment group 1-3 seconds, and finishing the experiment after the experiment, sequentially stopping the experiment, and finishing the experiment after the experiment, sequentially recording the symptoms of the experiment, and sequentially stopping the experiment.
The control group (including control group 1 and control group 2) was operated in substantially the same manner as the experimental group, except that pure water was used for the control group.
The results before and after the experiments of the experimental group 1 and the experimental group 2 are shown in the following tables 1 and 2, respectively.
TABLE 1
Note that: the scores in table 1 are full 10 points, and the volunteers score themselves according to their own conditions, with higher scores representing greater degrees of difficulty.
TABLE 2
Note that: the scores in table 2 are full 10 points, and the volunteers score themselves according to their own conditions, with higher scores representing greater degrees of difficulty.
The results before and after the experiments of the control group 1 and the control group 2 are shown in the following tables 3 and 4, respectively.
TABLE 3 Table 3
Note that: the score in table 3 is a full score of 10, and the volunteer self-scores the score according to his own situation, with a higher score representing a greater level of difficulty.
TABLE 4 Table 4
Note that: the score in table 4 is a full score of 10, and the volunteer self-scores the score according to his own situation, with a higher score representing a greater level of difficulty.
From the experimental results shown in tables 1, 2, 3 and 4, the rhinitis drug provided in the embodiment 1 of the invention can enable nasal mucosa to be separated from an allergic state within 10-20 minutes, has a desensitizing speed faster than that of the existing drug, can effectively inhibit the situation of running and nasal discharge, and can alleviate the symptom of nasal obstruction, meanwhile, the drug has no obvious toxic or side effect on human bodies, and can inhibit viruses in nasal cavities. The application method of the rhinitis medicine adopts a progressive method, firstly starts from low-concentration acetic acid solution and then gradually reaches high-concentration acetic acid solution, so that volunteers can adapt to the rhinitis medicine. The concentration of the medicine is reasonably set, so that the medicine can be suitable for rhinitis patients with different physiques, and the situation that the rhinitis patients are unacceptable because the high-concentration acetic acid solution has overlarge stimulation to the rhinitis patients is avoided.
The cold drug provided in example 2 has similar effects on nasal mucosa allergy such as nasal obstruction and nasal discharge caused by cold in volunteers, and can be referred to in tables 1 and 2.
The above examples are only preferred embodiments of the present invention, and are merely for illustrating the present invention, not for limiting the present invention, and those skilled in the art should not be able to make any changes, substitutions, modifications and the like without departing from the spirit of the present invention.
Claims (8)
1. A rhinitis medicine, which is characterized by comprising acetic acid solution.
2. The rhinitis drug of claim 1, wherein the acetic acid solution has a mass percentage concentration of greater than 7%.
3. The rhinitis drug of claim 2, wherein the acetic acid solution has a mass percentage concentration of 7% -30%.
4. The rhinitis drug of claim 1, wherein the acetic acid solution comprises 10% by mass acetic acid solution, 14% by mass acetic acid solution, 18% by mass acetic acid solution, 22% by mass acetic acid solution, 26% by mass acetic acid solution, and 30% by mass acetic acid solution.
5. A cold medicament, which is characterized by comprising acetic acid solution.
6. The cold medicament according to claim 5, wherein the acetic acid solution has a mass percentage concentration of more than 7%.
7. The cold medicament according to claim 6, wherein the acetic acid solution has a mass percentage concentration of 7% -30%.
8. The cold medicament according to claim 5, wherein the acetic acid solution comprises 10% by mass of acetic acid solution, 14% by mass of acetic acid solution, 18% by mass of acetic acid solution, 22% by mass of acetic acid solution, 26% by mass of acetic acid solution, and 30% by mass of acetic acid solution.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410056754.2A CN117883426A (en) | 2024-01-16 | 2024-01-16 | Rhinitis medicine and cold medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410056754.2A CN117883426A (en) | 2024-01-16 | 2024-01-16 | Rhinitis medicine and cold medicine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117883426A true CN117883426A (en) | 2024-04-16 |
Family
ID=90650218
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410056754.2A Pending CN117883426A (en) | 2024-01-16 | 2024-01-16 | Rhinitis medicine and cold medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117883426A (en) |
-
2024
- 2024-01-16 CN CN202410056754.2A patent/CN117883426A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100354608B1 (en) | Pharmaceutical compositions for preventing and treating allergic diseases and methods for preparation thereof | |
| US5240694A (en) | Combined antiviral and antimediator treatment of common colds | |
| US5508282A (en) | Composition and method for treating acute or chronic rhinosinusitis | |
| EP0661967A1 (en) | Combined virustatic antimediator (covam) treatment of common colds | |
| Palmer et al. | A comparison of two dose regimens of epsilon aminocaproic acid in the prevention and management of secondary traumatic hyphemas | |
| US4689223A (en) | Method of treating the symptoms of the common cold | |
| EP0768819A1 (en) | Combined virustatic antimediator (covam) treatment of common colds | |
| CN103735496B (en) | Compound collunarium gel for the treatment of of allergic rhinitis disease and preparation method thereof | |
| CN117883426A (en) | Rhinitis medicine and cold medicine | |
| CN110179843B (en) | External-use pharmaceutical composition for treating non-allergic rhinitis | |
| CN111821423B (en) | Application of interleukin 2 in treating chronic idiopathic urticaria | |
| CN101125199B (en) | Application of interleukin 2 in preparing medicine for treating rhinitis | |
| CN111991372B (en) | Application of medical skin repairing paste in preparation of dermatitis treatment medicine | |
| CN112006988B (en) | Application of medical skin repair spray in preparation of dermatitis treatment medicine | |
| US20220362190A1 (en) | Viral inactivation spray and gargling formulation | |
| CN109568428B (en) | Yongquan plaster for children | |
| RU2270692C1 (en) | Prolonged interferon solution | |
| EP0288632B1 (en) | Compositions for treating the symptoms of or preventing the common cold | |
| Qian et al. | Clinical effect analysis of budesonide atomization inhalation in the treatment of neonatal pneumonia | |
| EP1789061A1 (en) | Copd treatment and medicament | |
| CN111603485A (en) | Medicine formula for treating rhinitis and preparation method | |
| CN109078077A (en) | A kind of Traditional Chinese medicinal aerosol for treating pharyngo-laryngitis chronica | |
| Vysotska et al. | Development of composition and technology of extemporaneous ointment for treatment of allergic rinitis | |
| CN116211932A (en) | Medicine for treating rhinitis combined with acute pharyngitis caused by wind-heat of lung channel and preparation method thereof | |
| RU1780749C (en) | Method for treating chronic bronchitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |